Ida Franiak-Pietryga1,2* and Bradley Messmer2
1Department of Clinical and Laboratory Genetics, Medical University of Lodz, Poland
2University of California San Diego, Moores Cancer Center, USA
Chronic lymphocytic leukemia (CLL) has considerable change since the time clinical staging was introduced in clinical practice in 1975. Over the years, the prognostic factors analyses in CLL have expanded, and thus treatment considerably changed. Based on discovery of specific mutations, several targeted therapies have been introduced. This progress is continuing and finally chimeric antigen receptor against T cells (CART) is in the process of being developed. This review is an attempt to summarize the major benchmarks in the CART therapy of CLL.
Chronic lymphocytic leukemia; CAR-T cell therapy; ROR1
Franiak-Pietryga I. CAR-T – The Future Promising Therapy for CLL: A Mix between Cell Therapy, Gene Therapy and Immune-Oncology. Am J Leuk Res. 2017;1(2):1006.